A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT07294625
Phase
EARLY_PHASE1
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • LVIVO-TaVec200 product
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Xuzhou, Jiangsu, China|34.20442,117.28386
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Xi’an, Shanxi, China|35.99785,113.52486

Key Eligibility Criteria

  • Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtai…
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Has measurable lesions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →